| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3284648 | Clinical Gastroenterology and Hepatology | 2008 | 7 Pages |
Abstract
Infliximab therapy is associated with dramatic increases in BSAP and P1NP, consistent with inhibition of tumor necrosis factor-α effects on osteoblasts. The increases in CTX-1 and DPD likely reflect coupling of bone formation and resorption and increases in linear growth.
Keywords
CTx-1deoxypyridinolineDPDP1NPRANKLOPGPCDAIBSAPOsteoprotegerinbone specific alkaline phosphatasestandard deviationinterleukinELISAEnzyme-linked immunosorbent assayTumor necrosis factor–alphastandard errorREACHbody mass indexBMIPediatric Crohn's Disease Activity IndexTNF-αreceptor activator of nuclear factor kappa B ligand
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Meena Thayu, Mary B. Leonard, Jeffrey S. Hyams, Wallace V. Crandall, Subra Kugathasan, Anthony R. Otley, Allan Olson, Jewel Johanns, Colleen W. Marano, Robert B. Heuschkel, Gigi Veereman-Wauters, Anne M. Griffiths, Robert N. Baldassano,